Gene therapy: How Veristat cut trial database costs by 30%

This piece originally appeared in Pharmaceutical Technology.

The gene therapy market is predicted to experience rapid growth over the coming years. But with that growth will come many complexities that contract research organizations (CROs) must navigate to keep these unique clinical trials on track.

Despite just 39 different gene therapies recorded on the market in June 2023, according to GlobalData figures, more than 4,450 gene therapy drugs are currently in preclinical and clinical trials.

GlobalData’s State of the Pharmaceutical Industry 2024 report predicts that oncology will account for 44% of the cell and gene therapy (CGT) market by 2029. Trials are also increasing in other therapeutic areas, signalling the increase in research funding and product opportunity for diseases such as hemophilia, Alzheimer’s, primary immunodeficiencies, and even hereditary blindness.

Despite scientific and technological advances, the cost of gene therapy trials remains a significant hurdle, and reducing expenses is a considerable challenge given the inherent complications of such trials. That means CROs must find a middle ground for optimizing results within budget constraints.

With a limited number of patients available for trials of rare disease treatments, ensuring accurate data collection and recordkeeping is vital. All the more reason why executing your clinical trials with the right data management platform is key for achieving accurate data collection, significant savings on trial costs, and a return on investment for pharma and biotech companies, while also ensuring more patients can access the transformative treatments coming from gene therapy trials.

The challenges of accurate data collection for cell and gene therapies

Many of the genetic disorders that can be treated with gene therapy are extremely rare – with some affecting just one person in a million. Gene therapy trials are limited by the number of patients available with certain conditions. As a result, it is vital to make full use of any data gathered.

CGT trials require scrupulous management of patients, sites, and sponsors to deliver successful outcomes. In the modern pharma industry, electronic data capture (EDC) has emerged as the best way to reduce inefficiencies, streamline data capture, and optimize a trial’s results.

“Data is of the most critical value for success, and that dependency on data is only going to increase more and more,” notes Shao. “However, in a CGT trial, we identified that it is hard for the typical EDC to be able to capture all the data and adapt to the changes you need very quickly.”

Mismanagement of patient data can trigger trial integrity risk or minimally cause inefficiencies in data collection, and place extra burden on sites and CROs to resolve discrepancies. With gene therapy trial costs already running high, CROs must do everything they can to eliminate these risks and inefficiencies to ensure trials stay compliant, on schedule, and within budget.

Moreover, because CGT trials often recruit from a very small patient pool, patient dropouts can severely disrupt a trial and add further costly delays. For cell and gene therapies, the deployment of an effective ePRO solution is critical for helping to foster patient engagement in trials, solicit patient input conscientiously, and ensure that patients understand everything required of them.

“I worked on a Phase I cell therapy trial when I was a statistician myself, and it was very different from a typical Phase I study,” explains Shao. “There were a lot of unexpected challenges along the way regarding data and patients. You don’t know how patients are going to react to some of these investigational therapies. So, you need to have the ability to quickly adjust your database as the study goes – and typical EDC setups aren’t always able to accommodate this.”

Enabling significant cost savings for gene therapy trials

For their CGT trials, Shao and her team at Veristat have been using the cloud-based EDC platform from Zelta by Merative. The Zelta platform is uniquely flexible and scalable, allowing users to choose the modules they want for their study, making it compatible with virtually all trial types, regardless of complexity or size.

At its core, a trial’s main purpose is to produce reliable data to understand the efficacy and safety of new treatments. Accurately recording a patient’s experience is vital. Yet an overcomplicated, hard-to-use EDC platform can also result in data anomalies due to a lack of user understanding, misinterpretations, or data that are missing entirely. The Zelta platform manages highly complex processes without compromising usability, thanks to features like flexible page layouts and automated queries, enabling CGT trial operators to get the most out of their data.

Shao estimates that Veristat has “reduced clinical database costs by approximately 30%” in certain trials, resulting in highly significant savings. Compared to other EDC solutions, Zelta has also helped Veristat reduce the database build duration of their complex CGT trials from as long as 10 weeks to eight or less.

Platformed to improve patient engagement

Alongside reducing the timeframe for launching life-saving therapies to the market, Veristat found that the Zelta platform – which offers ePRO integrated with EDC – reduces the burden of technology integrations, both making managing patient data easier and helping patients engage better with trial processes.

Zelta EDC makes transferring patients from one site to another smoother. In long-term studies, patients regularly move to a different place, requiring their data to be easily transferred. Zelta EDC simplifies this process, thereby enhancing patient engagement.

Additional integrated modules, such as ePRO and eCOA forms, help improve a patient’s understanding of their own conditions and treatments, while also reducing a CRO’s workload by automatically transporting inputted data to case report forms (CRFs). Scheduled notifications offered by the ePRO remind patients to input data at the right times and ensure that databases remain accurate.

“For rare disease studies, you don’t have a lot of patients – you can’t lose them,” says Shao. “Zelta’s translation functionalities are especially important for CGT trials, as patients are distributed across the globe and speak different languages. This feature has absolutely made comprehension for patients far simpler. The Zelta platform is easy to use and has made the trial experience less stressful for patients, which is also highly important.”

Zelta’s high performance and the willingness of their team to support customers so that the platform can adapt to any trial’s needs are further key benefits from a CRO perspective.

Adaptable, scalable, and intuitive for patients, Zelta can help CROs manage data demands for even the most complex cell and gene therapy trials.

Explore how Zelta is supporting CROs.